XML 43 R29.htm IDEA: XBRL DOCUMENT v3.21.1
Long-Term Investments (Tables)
 3 Months Ended
Mar. 31, 2021
Long Term Investment [Abstract]  
Schedule of ownership percentages of investee
   Ownership percentage    
   March 31,   December 31,   Accounting
Name of related party  2021   2020   treatments
Braingenesis Biotechnology Co., Ltd.   0.17%   0.17%  Cost Method
Genepharm Biotech Corporation   0.70%   0.70%  Cost Method
BioHopeKing Corporation   5.90%   5.90%  Cost Method
BioFirst Corporation   15.99%   15.99%  Equity Method
Rgene Corporation   31.62%   31.62%  Equity Method
Schedule of extent the investee relies
Name of related party   The extent the investee relies on the Company for its business  
Braingenesis Biotechnology Co., Ltd.   No specific business relationship
Genepharm Biotech Corporation   No specific business relationship
BioHopeKing Corporation   Collaborating with the Company to develop and commercialize drugs
BioFirst Corporation   Loaned from the investee and provides research and development support service
Rgene Corporation   Collaborating with the Company to develop and commercialize drugs
Schedule of long-term investment
   March 31,
2021		   December 31,
2020		 
         
Non-marketable Cost Method Investments, net        
Braingenesis Biotechnology Co., Ltd.  $7,742   $7,853 
Genepharm Biotech Corporation   23,638    23,974 
BioHopeKing Corporation   878,056    890,564 
Sub total   909,436    922,391 
Equity Method Investments, net          
BioFirst Corporation   217,448    268,336 
Rgene Corporation   -    - 
Total  $1,126,884   $1,190,727 
Schedule of balance sheets
   March 31,
2021		   December 31,
2020		 
         
Current Assets  $1,216,963   $1,299,822 
Non-current Assets   2,633,925    2,540,041 
Current Liabilities   1,959,919    1,986,340 
Non-current Liabilities   76,082    73,197 
Stockholders’ Equity   1,814,887    1,780,326 
   March 31,
2021		   December 31,
2020		 
         
Current Assets  $107,682   $123,958 
Noncurrent Assets   395,665    412,342 
Current Liabilities   1,451,387    1,392,756 
Noncurrent Liabilities   28,877    38,953 
Shareholders’ Deficit   (976,917)   (895,409)
Schedule of statements of operation
   Three Months Ended
March 31,		 
   2021   2020 
     
Net sales  $12,239   $12,110 
Gross profit   7,080    1,578 
Net loss   (220,855)   (325,652)
Share of losses from investments accounted for using the equity method   (47,791)   (70,411)
    Three Months Ended
March 31,		  
    2021     2020  
       
Net sales   $ -     $ -  
Gross Profit     -       -  
Net loss     (95,395 )     (21,889 )
Share of loss from investments accounted for using the equity method     -       -  
Schedule of equity investments
   Three Months Ended
March 31,		 
   2021   2020 
         
Share of equity method investee losses  $(47,791)  $(70,411)